Paranovus Entertainment Technology (PAVS) Fundamentals 2026 — Revenue Analysis | SniperIQ
Paranovus Entertainment Technology (PAVS) is a US-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of
Paranovus Entertainment Technology (PAVS) has a market capitalization of approximately
Paranovus Entertainment Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Paranovus Entertainment Technology runs a net profit margin of -51.5%, a gross margin of 9.7%, and an operating margin of -14.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Paranovus Entertainment Technology reported revenue of $71,542 for fiscal year 2024, with net income of -$8M and earnings per share (EPS) of -10.686. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Paranovus Entertainment Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Paranovus Entertainment Technology carries a debt-to-equity ratio of 0.24x and a current ratio of 1.15x, with a market beta of -0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Paranovus Entertainment Technology (PAVS) the key facts are: market cap
Get Paranovus Entertainment Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.